Preoperative stop or continue? New antithrombotic and anticoagulants

Acta Anaesthesiologica Belgica

Volumn 52, Issue 4, 2001, Pages 385-393

  Ickx, B E ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HIRUDIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PENTASACCHARIDE; PYRIDINE DERIVATIVE; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TIROFIBAN;

ANESTHESIOLOGICAL TECHNIQUES; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; VEIN THROMBOSIS;

ANTICOAGULANTS; COUMARINS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREOPERATIVE CARE; RECEPTORS, PURINERGIC P2; RISK FACTORS; THROMBOSIS; THROMBOXANE A2;

EID: 0035678811     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Mortality by cause for eight regions of the world, global burden of disease study
2. New anticoagulant drugs
3. Platelet-active drugs. The relationships among dose, effectiveness, and side effects
4. Antiplatelet agents in cardiology, the choice of therapy
5. Low molecular weight heparin
6. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
7. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease
8. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients
9. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin inn healthy volunteers
10. New treatment options for heparin-induced thrombopenia
11. Use of recombinant hirudin as antithrombotic treatment in patients with heparin induced thrombocytopenia
12. A comparison of recombinant hirudin with low molecular weight heparin to prevent thromboembolic complications after total hip replacement
13. The relationship between hirudin and activated clotting time, implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery
14. Anticoagulation, the present and the future
15. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin. Pulmonary embolism prevention (PEP) trial
16. Hemorrhage and the use of blood products after adult cardiac operations, myths and realities
17. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
18. Perioperative activation of hemostasis in vascular surgery
19. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment
20. Hasards of aspirin withdrawal before transurethral prostatectomy
21. Hasards of aspirin withdrawal before transurethral prostatectomy
22. Ischelic heart attacks following cessation of aspirin before coronary artery bypass surgery, a report of two cases
23. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotic stenosis?
24. Antiplatelet drugs in femoropopliteal vein bypasses, a multicenter trial
25. Aortocoronary saphenous vein graft disease, pathogenesis, predisposition and prevention
26. The effect of ticlopidine upon platelet function, haemorrhage and postoperative thrombosis in patients undergoing suprapubic prostatectomy
27. Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafting
28. Catastrophic outcomes of noncardiac surgery soon after coronary stenting
29. Antiplatelet therapy with ticlopidin increases blood loss and transfusion in coronary bypass surgery
30. Clinical experience in coronary bypass surgery for abciximab treated patients
31. Abciximab and bleeding during coronary surgery, results from the EPILOG and EPISTENT trials. Improve longterm outcome with abciximab GP IIbIIIa inhibition in Stenting
32. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
33. Emergency coronary artery bypass surgery in abciximab treated patients
34. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
35. Current status of cardiac surgery in the abciximab treated patient
36. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
37. Les antivitamine K, indications et gestion en chirurgie urgente et non urgente
38. Prevention of venous thromboembolism
39. Timining of initial administration of low-molecular weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty
40. Low molecular weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patoients, a double-blind, randomised comparison
41. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations
42. The PENTATHLON, 2000 study, comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
43. The EPHESIUS study, comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
44. The PENTHIFRA study, comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after hip fracture surgery
45. The PENTAMAKS study, comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective major knee surgery
46. Regional anesthesia and anticoagulation
47. Belgian guidelines concerning drug induced alteration of coagulation and central neural blockade
48. AP-HP Comité scientifique thrombose. Prophylaxie des thomboses veineuses postopdratoires, recommandations de l'assistance publiqie-hôpitaux